Withdrawal of Diazoxide Choline Extended-Release (DCCR) Tablets Worsens Hyperphagia and Increases Weight and BMI in a 16-Week Double-Blind, Placebo-Controlled, Randomized Withdrawal Period in Patients With Prader-Willi Syndrome

Read more

Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Participants with Prader-Willi Syndrome from the Completed C601 Randomized Double-Blind Placebo-Controlled Study (DESTINY PWS) and C602 Open Label Extension (OLE) Study

Read more

Relaxation of Food Control Parameters Based on Improvements in the Food Safe Zone Questionnaire Occurs with Reduction of Hyperphagia in Clinical Trials of Diazoxide Choline Extended Release (DCCR) in Participants with Prader-Willi Syndrome.

Read more

Long-term Efficacy Results of Diazoxide Choline Extended-Release (DCCR) Tablets in Participants with Prader-Willi Syndrome from the Completed C601 (DESTINY PWS) and C602 Open Label Extension (OLE) Studies.

Read more

European Society for Paediatric Endocrinology, 2024

Read more

Endocrine Society Annual Meeting, 2024

Read more

Pediatric Endocrine Society, 2024

Read more